FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-028							
1	Estimated average k	ourdon							

	Check this box if no longer subject to
\neg	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Name and Address of Reporting Person* Mattessich Antony C.					2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [OCUL]											ip of Reporting Person(s) to Is iplicable) actor 10% C		to Issue % Own		
1 ` '						3. Date of Earliest Transaction (Month/Day/Year) 08/20/2018									X Officer (give title C below) be President & CEO					pecify
(Street) BEDFORD MA 01730 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tabl	e I - No	n-Deriv	ative	Sec	curitie	s Acc	quired,	Dis	posed o	f, or	Ben	eficia	ally (Owne	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						Execution Date,		Date,	Transaction Dis Code (Instr. 5)		Disposed	ecurities Acquired (A) posed Of (D) (Instr. 3, 4			4 and Se Be Ov		ount of ities icially d Following ted	6. Ownersh Form: Direc (D) or Indire (I) (Instr. 4)	t of ct Be Ov	7. Nature of Indirect Beneficial Ownership (Instr. 4)
										v	Amount		A) or D)	Price		Transaction(s) (Instr. 3 and 4)			(11301. 4)
Common Stock 08/20/2)/2018				P		20,000	0 A \$		\$5.9	95 ⁽¹⁾ 57,900		7,900	D		
		Та									sed of, onvertib				y Ov	vned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)			Date,	Code (8)	Transaction Of Code (Instr. Sec Acq (A) Disport of (I		ative rities ired psed . 3, 4	6. Date Exerci Expiration Dat (Month/Day/Ye		е	7. Title and Amount of Securities Underlying Derivative Security (Instrand 4) Amount or Numbro of Title Share:		ount nber	ıt r		9. Number of derivative Securities Beneficially Owned Following Reported Transactions (Instr. 4)	Owners Form: Direct (I or Indire (I) (Insti	nip of Be O) Ov ct (In	1. Nature of Indirect seneficial Dwnership Instr. 4)	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.93 to \$5.97, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

/s/ Donald Notman, as

08/21/2018 Attorney-in-Fact for Antony

Mattessich

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.